出典:Wikipedia
出典:『Wikipedia』 (2011/04/27 06:59 UTC 版)
Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma. Touted as a drug of the future, Metelimumab was dropped from further development in favour of GC-1008, which is currently being developed by Genzyme.